cbdMD Statistics
Total Valuation
cbdMD has a market cap or net worth of $9.68 million. The enterprise value is $8.19 million.
Important Dates
The next estimated earnings date is Thursday, February 12, 2026, after market close.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
cbdMD has 8.96 million shares outstanding. The number of shares has increased by 646.22% in one year.
| Current Share Class | 8.96M |
| Shares Outstanding | 8.96M |
| Shares Change (YoY) | +646.22% |
| Shares Change (QoQ) | +54.96% |
| Owned by Insiders (%) | 7.97% |
| Owned by Institutions (%) | 9.56% |
| Float | 8.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.23 |
| Forward PS | 0.49 |
| PB Ratio | 1.33 |
| P/TBV Ratio | 1.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.05, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.05 |
| Quick Ratio | 1.03 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 2.21 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.42% and return on invested capital (ROIC) is -24.05%.
| Return on Equity (ROE) | -44.42% |
| Return on Assets (ROA) | -12.87% |
| Return on Invested Capital (ROIC) | -24.05% |
| Return on Capital Employed (ROCE) | -29.93% |
| Revenue Per Employee | $456,916 |
| Profits Per Employee | -$104,176 |
| Employee Count | 42 |
| Asset Turnover | 1.83 |
| Inventory Turnover | 2.64 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.89% in the last 52 weeks. The beta is 2.10, so cbdMD's price volatility has been higher than the market average.
| Beta (5Y) | 2.10 |
| 52-Week Price Change | -72.89% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 47.05 |
| Average Volume (20 Days) | 32,383,461 |
Short Selling Information
The latest short interest is 229,562, so 2.56% of the outstanding shares have been sold short.
| Short Interest | 229,562 |
| Short Previous Month | 2.41M |
| Short % of Shares Out | 2.56% |
| Short % of Float | 2.78% |
| Short Ratio (days to cover) | 0.19 |
Income Statement
In the last 12 months, cbdMD had revenue of $19.19 million and -$4.38 million in losses. Loss per share was -$1.09.
| Revenue | 19.19M |
| Gross Profit | 11.97M |
| Operating Income | -2.16M |
| Pretax Income | -2.04M |
| Net Income | -4.38M |
| EBITDA | -1.04M |
| EBIT | -2.16M |
| Loss Per Share | -$1.09 |
Full Income StatementBalance Sheet
The company has $2.26 million in cash and $778,240 in debt, with a net cash position of $1.48 million or $0.17 per share.
| Cash & Cash Equivalents | 2.26M |
| Total Debt | 778,240 |
| Net Cash | 1.48M |
| Net Cash Per Share | $0.17 |
| Equity (Book Value) | 7.23M |
| Book Value Per Share | 0.81 |
| Working Capital | 3.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.45 million and capital expenditures -$184,172, giving a free cash flow of -$1.64 million.
| Operating Cash Flow | -1.45M |
| Capital Expenditures | -184,172 |
| Free Cash Flow | -1.64M |
| FCF Per Share | -$0.18 |
Full Cash Flow StatementMargins
Gross margin is 62.37%, with operating and profit margins of -11.27% and -10.63%.
| Gross Margin | 62.37% |
| Operating Margin | -11.27% |
| Pretax Margin | -10.63% |
| Profit Margin | -10.63% |
| EBITDA Margin | -5.40% |
| EBIT Margin | -11.27% |
| FCF Margin | n/a |
Dividends & Yields
cbdMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -646.22% |
| Shareholder Yield | -646.22% |
| Earnings Yield | -45.22% |
| FCF Yield | -16.91% |
Analyst Forecast
The average price target for cbdMD is $2.00, which is 85.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.00 |
| Price Target Difference | 85.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 7, 2025. It was a reverse split with a ratio of 1:8.
| Last Split Date | May 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
cbdMD has an Altman Z-Score of -21.75 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.75 |
| Piotroski F-Score | 4 |
